anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
TREXIMET is a fixed combination containing doses of sumatriptan (85 mg) and naproxen sodium (500 mg) within the approved dosage ranges of the individual components (25 to 100 mg of sumatriptan and 220 to 825 mg of naproxen sodium). TREXIMET contains a dose of sumatriptan higher than the lowest effective dose. Individuals may vary in response to doses of sumatriptan. The choice of the dose of sumatriptan, and of the use of a fixed combination such as in TREXIMET should therefore be made on an individual basis, weighing the possible benefit of a higher dose of sumatriptan with the potential for a greater risk of adverse events. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET.

The recommended dose is 1 tablet. In controlled clinical trials, single doses of TREXIMET were effective for the acute treatment of migraine in adults (see CLINICAL TRIALS).

The efficacy of taking a second dose has not been established. Do not take more than 2 TREXIMET tablets in 24 hours. Dosing of tablets should be at least 2 hours apart. The safety of treating an average of more than 5 migraine headaches in a 30-day period has not been established.

TREXIMET may be administered with or without food. Tablets should not be split, crushed, or chewed.

The combined use of TREXIMET with MAO-A inhibitors or use of TREXIMET within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated (see CONTRAINDICATIONS, CLINICAL PHARMACOLOGY: Drug Interactions, PRECAUTIONS: Drug Interactions).

TREXIMET and any ergotamine-containing or ergot-type medication (like dihydroergotamine or methysergide) should not be used within 24 hours of each other. TREXIMET and other 5-HT1 agonists should not be administered within 24 hours of each other (see CONTRAINDICATIONS and PRECAUTIONS: Drug Interactions).

TREXIMET is contraindicated in patients with hepatic impairment (see CONTRAINDICATIONS and CLINICAL PHARMACOLOGY: Special Populations).

TREXIMET is not recommended for use in patients with creatinine clearance less than 30 mL/min (see CLINICAL PHARMACOLOGY: Special Populations and PRECAUTIONS: Renal Effects).
The invention belongs to the field of bioengineering, and provides a bacteriophage capable of entering blood through oral administration and application of the bacteriophage. The bacteriophage monomer is a colibacteriophage; the Latin name is E.coli phage; the bacteriophage is named as Bp4; the bacteriophage has broad-spectrum sterilization capability on escherichia coli; the bacteriophage Bp4 is preserved in the general microbiology center of China Committee for Culture Collection of Microorganisms; the preservation date is 10th June, 2014; the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.9248. The bacteriophage has the strong cracking effect on the escherichia coli; bacteriophage sources are provided for industrial bacteriophage production, chicken colibacillosis prevention and control and environment sterilization, so that the severe escherichia coli viruses in a chicken farm are controlled. The bacteriophage can be used for industrial production, and the host bacterial escherichia coli specific amplification is realized. The bacteriophage can be used as a safe biological sterilization agent for environment sterilization. The bacteriophage can be used as biological antibiotic substitute to be applied to disease control in the chicken farm.
The incidence of malignant tumors of digestive system is increasing year by year in the world, and surgical treatment is the first choice for malignant tumors of digestive system. Most of these patients were elderly, had more complications before surgery, had greater surgical trauma, and had a high proportion of postoperative ICU admission. In recent three years, 28.1% of patients with malignant tumor of digestive system were admitted to ICU after surgery. The study found that postoperative ICU care in critically ill patients was conducive to reducing mortality, while non-essential postoperative ICU care in some patients was associated with the worst outcome. At present, there is still a lack of accurate and reliable decision making system for postoperative admission to ICU for patients with digestive system malignancies at home and abroad. Therefore, this project intends to establish a predictive model for postoperative ICU admission of patients with malignant tumors of the digestive system, develop a friendly interface that is convenient for medical care, help medical care quickly determine the biggest beneficiaries of postoperative ICU admission, rationally allocate medical resources, improve medical quality, reduce medical costs, ensure perioperative safety of patients, and promote postoperative rehabilitation of patients. At present, there is still a lack of accurate and reliable decision making system for postoperative admission to ICU for patients with digestive system malignancies at home and abroad. Therefore, this project intends to establish a predictive model for postoperative ICU admission of patients with malignant tumors of the digestive system, develop a friendly interface that is convenient for medical care, help medical care quickly determine the biggest beneficiaries of postoperative ICU admission, rationally allocate medical resources, improve medical quality, reduce medical costs, ensure perioperative safety of patients, and promote postoperative rehabilitation of patients.
Regenerative Peripheral Nerve Interfaces (RPNIs) encompass neurotized muscle grafts employed for the purpose of amplifying peripheral nerve electrical signaling. The aim of this investigation was to undertake an analysis of the extant literature concerning animal models utilized in the context of RPNIs. A systematic review of the literature of RPNI techniques in animal models was performed in line with the PRISMA statement using the MEDLINE/PubMed and Embase databases from January 1970 to September 2023. Within the compilation of one hundred and four articles employing the RPNI technique, a subset of thirty-five were conducted using animal models across six distinct institutions. The majority (91%) of these studies were performed on murine models, while the remaining (9%) were conducted employing macaque models. The most frequently employed anatomical components in the construction of the RPNIs were the common peroneal nerve and the extensor digitorum longus (EDL) muscle. Through various histological techniques, robust neoangiogenesis and axonal regeneration were evidenced. Functionally, the RPNIs demonstrated the capability to discern, record, and amplify action potentials, a competence that exhibited commendable long-term stability. Different RPNI animal models have been replicated across different studies. Histological, neurophysiological, and functional analyses are summarized to be used in future studies.
<P>PROBLEM TO BE SOLVED: To provide a more efficient and more effective means for treating or preventing transcription factor-related diseases and disorders.  <P>SOLUTION: The cyclic dumbbell oligodeoxynucleotide (CDODN) having two loop structures and one stem structure is provided, wherein the stem structure contains a nucleotide sequence bindable to a DNA-bound domain of a transcription factor. A pharmaceutical composition containing the above CDODN is also provided. This pharmaceutical composition is usable for treating and/or preventing such transcription factor-related diseases or disorders. The method for using this composition comprises administering a subject with a curatively effective amount of a CDODN having two loop structures and one stem structure, wherein the stem structure contains a nucleotide sequence bindable to the transcription factor's DNA-bound domain.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder involving the brain-gut interaction. IBS is characterized by persistent abdominal pain and changes in bowel habits. IBS exerts significant impacts on quality of life and imposes huge economic costs. Global epidemiological data reveal variations in IBS prevalence, both globally and between genders, necessitating comprehensive studies to uncover potential societal and cultural influences. While the exact pathophysiology of IBS remains incompletely understood, the mechanism involves a dysregulation of the brain-gut axis, leading to disturbed intestinal motility, local inflammation, altered intestinal permeability, visceral sensitivity, and gut microbiota composition. We reviewed several gender-related pathophysiological aspects of IBS pathophysiology, by focusing on gut dysbiosis and intestinal permeability. This perspective paves the way to personalized and multidimensional clinical management of individuals with IBS.
Participants (patient-sleep-partner caregiver dyads) in this group will receive the My Sleep Our Sleep (MSOS) intervention. Total participation is up to 4 weeks.
OBJECTIVES: To determine the patterns of storing, using and disposing of opioids among patients with advanced cancer followed at home.
METHODS: Patients who were prescribed opioids were selected. Prescribed opioids and their doses used for background pain and breakthrough pain were collected, as well as CAGE (cut down, annoyed, guilty and eye opener) for alcohol and drugs, smoking and history of illicit substance use. Questions regarding the opioid use, storage and disposal were posed.
RESULTS: 100 patients were surveyed. Fifty-one patients had unused opioids at home, 25 patients did not throw away the drugs, 40 patients saved opioids for future use and 35 patients were unaware of proper opioid disposal methods. A total of 28 patients reported unsafe use by sharing or losing their opioids; 12 patients were unaware that their opioid could be fatal when taken by others. Most patients acknowledged that pain medications could be dangerous when taken by others. Patients with a partner and who were married were more likely to keep their opioids locked (p=0.028 and p=0.025, respectively).
CONCLUSION: A large number of patients with advanced cancer followed at home do not store, use and dispose of opioids safely. Patient education programmes should be incorporated to decrease the availability of opioids at home for abuse, diversion, and accidental poisoning.
More and more colorectal surgeons believe that surgical resections of hepatic metastases from colorectal cancer is the only chance for cure of patients. The five-year survival for patients with hepatic metastasis from colorectal cancer after surgical resection is approximately 30 %. However, most hepatic metastases from colorectal cancer were inoperable. With the progress of chemotherapy, for example, the combination of the 5-Fu, leucovorin, and oxaliplatin, some surgeons advocated that approximately 20% of inoperable liver metastases will be converted to operable case, thus providing the long-term survival for patients. In this study, we made a phase Ⅱ clinical trial regarding the use of the Folfox-4 regimens in the neo-adjuvant treatment of inoperable hepatic metastases. Our aims is to evaluate the tumor response rate for this regimen, the rate of resectability of liver metastases, progression free survival and overall survival of patients. In addition, the difference between the reports from Western and Oriental countries will be analyzed. We believe this study will provide new perspectives regarding the most beneficial treatment modalities for the patients with hepatic metastases from colorectal cancer.
OBJECTIVES: I. Determine the toxicity of high-dose busulfan followed by interleukin-2 (IL-2) and sargramostim (GM-CSF) activated autologous/syngeneic peripheral blood stem cell (PBSC) transplantation, sequential IL-2 and GM-CSF therapy, and interferon alfa in patients with chronic myelogenous leukemia. II. Determine engraftment potential of IL-2/GM-CSF activated PBSC followed by sequential IL-2/GM-CSF therapy in this patient population. III. Assess the time to cytogenetic and/or morphologic relapse, overall event-free survival, and overall survival in these patients treated with this regimen.

OUTLINE: Autologous peripheral blood stem cells (PBSC) are harvested and activated with interleukin-2 (IL-2) and sargramostim (GM-CSF) on another protocol. Patients receive oral busulfan every 6 hours on days -6 to -3 for a total of 16 doses. IL-2 and GM-CSF-activated PBSC are reinfused on day 0. Beginning 4 hours after PBSC infusion, patients receive IL-2 IV continuously for 5 days followed by 2 days of rest for 4 weeks. In addition, GM-CSF is administered subcutaneously (SC) every Monday, Wednesday, and Friday for 4 weeks. Upon hematologic recovery, but no earlier than 2 weeks after IL-2 and GM-CSF, patients receive interferon alfa SC 3 times weekly until clear evidence of disease progression. Patients are followed every 6 months for 3 years and then annually thereafter.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 2-3 years.
136,757. Neville, E. M., and Withey, R. J. May 19, 1919. Teeth, artificial.-An adhesive for the fixation of artificial dentures consists of a mixture in the form of powder of gum tragacanth or similar gum with a substantially insoluble substance such as calcium carbonate, zinc oxide, calcium phosphate, talcum, baolin, kieselguhr, zinc carbonate, zinc oleate, zinc borate, slaked lime, amylum, or a mixture of such substances. An antiseptic, such as boric acid or thymol, and flavouring and colour. ing agents may also be added. A preferred composition consists of gun tragacanth, calcium oar. bonate, boric acid, and carmine.
60 Patients aged between 35 and 70 years with proximal humeral fracture and surgical treatment will be recruited in three different clinics in Germany and randomised into an intervention and a control group. Participants will be assessed before randomisation and followed up after completing an intervention period of 3 weeks and additionally after 3, 6 and 12 months. Baseline assessment will assess cognition (SOMC), level of pain in the affected arm, ability to work, gait speed (10m walk), disability of the arm, shoulder and hand (DASH), as well as the range of motion of the affected arm (goniometer measurement), visual acuity and motor function of orthopaedic patients (WMFT-O). Clinical follow up directly after intervention will assess disability of the arm, shoulder and hand (DASH), the range of motion and motor function (WMFT-O). Primary outcome parameter will be the DASH and secondary outcome parameter will be the WMFT-O. The long-term results will be assessed prospectively by a postal follow-up. All patients will receive conventional occupational- and physiotherapy. The intervention group will receive an additive robotic-assisted training using the Armeo®Spring robot for three weeks.
FIELD: food industry. ^ SUBSTANCE: invention relates to chemical and pharmaceutical and food industries and deals with a method for processing commercial Japanese sea cucumber (Cucumaria japonica) and a biologically active product produced by this method. The method involves milling cucumaria skin-muscular sac, its extraction with 96% ethyl alcohol under heating conditions, the extract separation, repeated extraction of the residue, supernatant separation by way of centrifugation and the extracts combination. Then the cucumaria tissue residue is air-dried at room temperature and vacuumised. Then the tissue residue is milled during 3-5 hours and strained through a sieve till the end product particles size is no more than 0.08 mm. The produced product has hepato-protective properties and contains the following basic components (wt %): protein- no less than 70, carbohydrates - 4.5-4.9, calcium - 1.5-1.9, sodium - 0.9-1.3, magnesium - 0.5-0.9, potassium - 0.2-0.6, alcohol - no more than 0.5%, moisture - no more than 10% and ashes - no more than 8%. ^ EFFECT: invention allows to more completely process a valuable biological raw material as well as manufacture a new product (being a source of indispensable amino acids and food fibres) used for prevention of toxic liver diseases. ^ 3 cl, 3 dwg, 5 tbl, 5 ex
This study started from the recruitment of subjects, confirmed diagnosis by clinical diagnosis and pathological biopsy, preliminary screening according to inclusion and exclusion criteria, and signing of informed consent. Patients who were evaluated as indications for surgical resection and underwent surgical treatment were treated with Smetinib bisulfate capsules. PFS, ORR, and DOR were evaluated after 6 cycles of administration of Simetinib bisulfate capsules (20-50mg bid) daily for 30 days, as individualized by patient body surface area (BSA).
Stage 1 consisted of a single arm where patients received BEZ235 300mg or 400mg bid. Initially the study started with a dose of 400mg bid. However, following an amendment after the preliminary safety and tolerability data from the first 3 patients treated at the 400mg dose, the dosage was changed to 300mg bid.
patients undergoing modified radical mastectomy were divided into two groups by computer. patients in catheter group were placed a catheter under clavipectoral fascia in the neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis at the 1/3 lateral part of clavicula. solution included 10 ml of %0.5 bupivacain, %1 lidocain, 10 ml %0.9 sodium chloride totally 30 ml were given via the catheter for postoperative analgesia at the end of surgery. patients in iv analgesia group were given 100 mg tramadol iv 30 minutes before extubation. Patients in both groups were given dexketoprofen 50 mg iv if the VAS score was over 4. VAS scores, rescue analgesic requirement and timing, complications were recorded and compared between groups 1, 6, 12, 24 hours and 90 days after surgery.
The invention provides a polylactic acid-cladded protein peptide vaccine, a protein peptide vaccine carrying system for a protamine-cladded polylactic acid nanocapsule and a preparing method of the carrying system. Ovalbumin (OVA) is used as a model protein peptide vaccine, and an OVA solution is dispersed in a PLA-containing methylene dichloride organic phase by a probe ultrasonography method to form a primary emulsion. The primary emulsion is added into a polyvinyl alcohol containing external aqueous phase and treated by probe ultrasonography to form a multiple emulsion. A cured OVA/PLA microcapsule is obtained after the methylene dichloride organic phase is fully volatilized through agitating. Protamine (PS) is added into an OVA/PLA microcapsule suspension and agitated to obtain an OVA/PLA/PS microcapsule. The OVA/PLA/PS microcapsule has stable nanometer grain size, stable dispersing coefficient and surface potential suitable for transfect cells. The extracting capability of bone marrow derived dendritic cells (BMDC) for the OVA/PLA/PS microcapsule can be effectively improved. The expression of BMDC surface molecules MHCI, MHCII, CD83 and CD86 is obviously improved, and the secretion of a BMDC polarizing factor IL-12p70 is increased.
Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot. In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days. Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase. Oral aripiprazole was available as rescue medication if necessary.
If subject is randomized into the hip spica cast group, subject will proceed to the operating room and be given general anesthesia to administer the spica cast. Cast will be used for up to 8 weeks, until adequate callous formation is confirmed.
Patients will receive a sound S1 while they generate a positive outcome of imagery rehearsal therapy (IRT). They will also receive the sound S1 during REM sleep.
Patients undergo both a CT liver perfusion study pre Y-90 treatment and a PET/CT of liver following Y-90 treatment. For the PET/CT no additional radioactivity is required.
PURPOSE: Non-motor symptoms, such as sleep disturbances, fatigue, neuropsychiatric manifestations, cognitive impairment, and sensory abnormalities, have been widely reported in patients with idiopathic cervical dystonia (ICD). This study aimed to clarify the autonomic nervous system (ANS) involvement in ICD patients, which is still unclear in the literature.
METHODS: We conducted a pilot case-control study to investigate ANS in twenty ICD patients and twenty age-sex-matched controls. The Composite Autonomic System Scale 31 was used for ANS clinical assessment. The laser Doppler flowmetry quantitative spectral analysis, applied to the skin and recorded from indices, was used to measure at rest, after a parasympathetic activation (six deep breathing) and two sympathetic stimuli (isometric handgrip and mental calculation), the power of high-frequency and low-frequency oscillations, and the low-frequency/high-frequency ratio.
RESULTS: ICD patients manifested higher clinical dysautonomic symptoms than controls (p < 0.05). At rest, a lower high-frequency power band was detected among ICD patients than controls, reaching a statistically significant difference in the age group of ≥ 57-year-olds (p < 0.05). In the latter age group, ICD patients showed a lower low-frequency/high-frequency ratio than controls at rest (p < 0.05) and after mental calculation (p < 0.05). Regardless of age, during handgrip, ICD patients showed (i) lower low-frequency/high-frequency ratio (p < 0.05), (ii) similar increase of the low-frequency oscillatory component compared to controls, and (iii) stable high-frequency oscillatory component, which conversely decreased in controls. No differences between the two groups were detected during deep breathing.
CONCLUSION: ICD patients showed ANS dysfunction at clinical and neurophysiological levels, reflecting an abnormal parasympathetic-sympathetic interaction likely related to abnormal neck posture and neurotransmitter alterations.
The invention provides a nucleic acid aptamer, wherein the nucleotide sequence of the nucleic acid aptamer is shown as one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 4, SEQ ID NO. 6, SEQ ID NO. 7 and SEQ ID NO. 8. The nucleic acid aptamer can be specifically and efficiently combined with PDGF-CC, so that the angiogenesis promotion effect of the PDGF-CC under pathological conditions is blocked, and the nucleic acid aptamer plays a role in treating diseases caused by hyperproliferation of new blood vessels.